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have been included in that analysis. In 
the event 50 patients were sufficient to 
raise a serious concern that the surgi-
cal component of multimodal treatment 
might in fact shorten life, and reduce its 
quality, amply illustrating the cogency 
of Lilford’s maxim “some unbiased evi-
dence is clearly better than none.”
To say that MARS had “an opera-
tive mortality substantially higher than 
that of any other contemporary series” is 
disingenuous. If there are zero, one, two, 
or three events in a series of 25, the per-
centage rates are 0%, 4%, 8%, and 12% 
and the exact confidence limits around 
these overlap widely. If there had been no 
perioperative deaths in MARS it would 
have been just as inappropriate to claim 
mortality to be substantially lower than 
in other reports (the upper 95% confi-
dence limit of 0 of 25 is 13.7%). The 
plain fact is that EPP mortality in MARS 
(2 of 19; 10.5%; exact 95% confidence 
limits 1.3%–33.1%) lies within the 
range of reported data: in a systematic 
review of 34 studies, including 2320 
patients, 30-day mortality ranged from 
0% to 11.8%.
MARS outcomes for patients 
allocated to surgery have external 
validity. The objective of EPP is not 
survival to 30 days (or one would not 
remove a lung, the pericardium, and the 
diaphragm) but rather better long-term 
survival, and in this regard MARS EPP 
results are entirely in line with major 
series in the literature. EPP cohorts of 
100, 385, 121, and 208 patients, pub-
lished from 2007 to 2009, reported 
median survival times of 10, 12, 13, and 
14 months, respectively.4 The median 
survival of patients in the EPP arm of 
MARS was 14.4 months from random-
ization. The important, and perhaps for 
some inconvenient, finding was that 
among patients considered suitable for 
EPP but randomized to not have surgery, 
the median survival was 19.5 months, 
better than among the EPP patients in 
MARS and better than among the surgi-
cal series cited above (Fig. 1).
The MARS results have broad 
clinical face validity. The results came 
as no great surprise to all except a small 
number of proponents of EPP. The effort 
in providing data that shows that EPP is 
not a proven treatment earned the 2012 
Lifetime Achievement Award of the 
British Thoracic Oncology Group.
The feasibility of performing 
randomized trials was demonstrated. 
MARS took 3 years (2005–2008) to 
register 112 patients, by signed con-
sent, into the first phase of the study. 
Only 18 withdrew of their own volition 
and, after clinical exclusions, 57 gave 
further signed consent to be random-
ized.1,4 The EORTC 08031 nonrandom-
ized observational study took 2 years 
(2005–2007) to recruit 59 patients and 
arguably the fair comparison would be 
with the accrual rate of 112 patients into 
the nonrandomized phase of MARS.5 
Rather than seeking to fault MARS it 
is surely time to put effort into finding 
high-quality evidence, for example, 
concerning the effectiveness of lung-
sparing surgery on quality of life, so 
that we can provide evidence-based 
advice to patients.
FIGURE 1.  Median survival of patients with and without EPP.
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Drs. Treasure, Utley, and O’Byrne 
write to correct what they consider to be 
misperceptions about the Mesothelioma 
and Radical Surgery (MARS) trial. 
Significant concerns about the methodol-
ogy used in this trial have already been 
reported by an international group of 
mesothelioma investigators1 and do not 
need to be reiterated here. A major con-
cern was that a trial, originally designed to 
accrue 50 patients with malignant pleural 
mesothelioma (MPM) to test the feasibil-
ity of randomizing between extrapleural 
pneumonectomy (EPP) versus no surgery, 
was reported as a definitive phase III trial 
showing no survival benefit for EPP. This 
is a fundamental violation of the principles 
of clinical trial analysis and reporting.
The focus of the article published 
in the November issue of the Journal of 
Thoracic Oncology2 and of the accompa-
nying editorial3 was the successful effort 
by the International Association for the 
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We thank Bölükbas et al. for their 
interest in our research. The main issue 
raised by Bölükbas et al. is that survival 
results and pattern of failure were not 
reported in our research, although we 
had a median follow-up of 19 months.
There are two main reasons not to 
present outcome data along with safety 
and feasibility results. First, in the pres-
ent article, we investigated the safety of 
delivering very high doses of radiation 
therapy to the intact lung. Twenty-five 
of 28 patients received 60 Gy in 25 
fractions. Our experience of using high 
radiation dose is the first reported in the 
literature, and we wanted to emphasize 
the toxicity results. Also, Rimner et al.1 
reported initial experience with pleural 
intensity-modulated radiation therapy 
in 36 patients with two intact lungs, 
however, the mean total dose was lower 
(48.6 Gy at 1.8 Gy/fraction). We also 
described the dosimetric performance 
of tomotherapy, and we found that a 
new dosimetric parameter, the contra-
lateral lung V5, was strongly correlated 
with the risk of pneumonitis.
Second, in our opinion, a median 
follow-up of 19 months is not enough 
to draw conclusion on survival. Good 
results in terms of survival were 
obtained with extrapleural pneumo-
nectomy plus radiation; therefore, we 
need very solid data (long follow-up) 
on survival with radical pleurectomy/
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tomotherapy after pleurectomy/decor-
tication or biopsy for malignant pleural 
mesothelioma (MPM). Administration 
of radiation to patients with two intact 
lungs is challenging and the authors 
have to be congratulated for their novel 
approach and the results with regard to 
acute and mid-term toxicities. Safety 
and efficacy have been proved in several 
studies for novel radiation techniques 
in terms of pleural intensity-modulated 
radiation therapy and tomotherapy.2 As 
MPM is a rare and rapidly fatal disease, 
knowledge about disease-free survival, 
overall survival, and patterns of failure 
are of great importance for every study 
reporting outcomes after treatment 
for MPM.
Patterns of local failure might be 
the most important test of adequate treat-
ment planning (clinical target volume 
[CTV]) and treatment success.3 The CTV 
going from the lung apex to the vicin-
ity of the L2 vertebral body is very well 
described. The median follow-up was 
19 months ranging from 6 to 29 months 
in this study. Thus, at least short-term 
and mid-term results should be avail-
able about treatment failures in terms 
of relapse within and/or outside CTV. 
Further more, because the interlobar 
pleura were not included in the CTV it 
would be interesting to see whether there 
were any differences of local recurrence 
within the area of the fissures in patients 
undergoing pleurectomy and patients 
only having undergone biopsy for MPM.
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Study of Lung Cancer Staging Committee 
to develop an international database that 
would lead to evidence-based revisions of 
the International Union Against Cancer 
(UICC) and American Joint Commission 
on Cancer (AJCC) staging system for 
MPM. Discussions of the role of EPP 
in the management of MPM or of the 
MARS trial are, frankly, tangential to the 
primary focus of this effort.
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To the Editor:
We read with great interest the 
important investigation by Minatel 
et al.1 reporting their experience with 
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